头针结合现代康复治疗小儿脑瘫临床研究

目的观察头针与现代康复疗法在治疗小儿脑瘫中的协同作用.方法90例脑瘫患儿随机分为3组,Ⅰ组采用头针疗法、Ⅱ组采用现代康复疗法和Ⅲ组采用头针结合现代康复疗法,治疗前后进行日常生活能力(ADL)、运动功能评定.结果经60天治疗后,3个组ADL评分明显高于治疗前(P<0.01),Ⅲ组的ADL评分、运动功能评分明显优于Ⅰ、Ⅱ组(P<0.01),Ⅰ、Ⅱ组相比则差异无显著性意义.结论头针与现代康复疗法在治疗小儿脑瘫中有协同作用.     

经皮电刺激与电针治疗纤维肌痛综合征疗效对比

目的 :对比经皮电刺激与电针治疗纤维肌痛综合征 (FS)的疗效差异。方法 :将 66例患者随机分为经皮电刺激治疗组 (A组 )、电针治疗组 (B组 )、药物对照组 (C组 )进行临床疗效的对比研究。其中A组和B组均采用以FS常见的 1 8个压痛点邻近穴位为刺激点 ,C组采用口服阿米替林为主的西药。结果 :A组及B组的有效率及痊愈显效者 6个月、1 2个月及 2 4个月随访结果同C组比较 ,其差异具有非常显著性意义 (P <0 0 1 ) ,但A组同B组比较 ,差异无显著性意义 (P >0 0 5)。结论 :经皮电刺激或电针刺激穴位治疗纤维肌痛综合征的疗效优于药物组 ,而经皮电刺激是一种无创痛且被患者乐于接受的方法     

人输卵管蛋白全长cDNA克隆及真核细胞中的表达

目的:克隆人输卵管蛋白(hOviductin)全长cDNA序列,真核细胞中表达,并了解hOviductin是否与大鼠卵母细胞结合。方法:构建人输卵管黏膜上皮细胞cDNA文库,以~(32)P标记的兔输卵管蛋白全长cDNA序列为探针,自文库中筛选hOviductin全长cDNA序列。将获得的hOviductin编码区cDNA序列插入pEGFP-N1真核表达载体,转染HeLa细胞,表达分泌重组的绿色荧光蛋白(EGFP)-hOviductin,并估量其浓度。激光扫描共聚焦显微镜下观察EGFP-hOviductin与大鼠卵巢的卵丘细胞-卵母细胞复合物(COC)或去除透明带后的裸卵的结合情况。结果:所构建的cDNA文库重组率为98.5％,滴度为1.1×10~6pfu/mL。克隆所得hOviductin全长cDNA约为2500 bp,Gen-Bank的登录号为AY189737。EGFP-hOviductin在条件培液中的浓度为0.236 nmol/L,能结合在去透明带的大鼠裸卵质膜外表面,而未见其与COC结合。结论:hOviductin能在HeLa细胞中表达分泌,其分泌产物可结合于大鼠裸卵质膜外表面。     

特区经济学的理论前提

实行特殊政策和实施特殊管理体制是世界经济特区共有的基本特征。正是这两个基本特征构成了特区经济学的两个理论前提。对经济特区实行特殊政策和实施特殊管理体制进行理论分析 ,目的在于为构筑特区经济学的理论体系作理论上的准备     

离子抑制色谱法测定琥乙红霉素含量及其有关物质

目的　建立离子抑制色谱法测定琥乙红霉素原料的含量及有关物质的方法 ,并研究其影响因素。方法　采用ZorbaxSB -C1 8色谱柱 ,以 0 .0 2mol·L- 1 KH2 PO4 乙腈 ( 4 5∶5 5 ,用氨试液调至pH 6 .8)为流动相 ,流速 1.2mL·min- 1 ,检测波长 2 10nm ,柱温 ( 30± 0 .5 )℃。结果　在选定固定相条件下 ,流动相对组分的洗脱和选择性影响最大 ,柱温次之 ,琥乙红霉素在乙腈中比较稳定。测定了有效主成分琥乙红霉素A的含量以及 7个有关物质的总含量 ,琥乙红霉素A的平均回收率为 99.4 5 %(RSD =2 .2 4 % ,n =5 )。结论　本方法可用于琥乙红霉素原料的含量测定和有关物质的检查。     

pH-敏感甲硝唑壳聚糖-聚乙烯吡咯烷酮水凝胶的研究

 目的 制备pH-敏感的壳聚糖-聚乙烯吡咯烷酮（PVP）水凝胶，作为甲硝唑治疗胃溃疡控释给药系统的载体。方法 用戊二醛交联适宜比例混合的壳聚糖、PVP混合物，负载甲硝唑或不负载甲硝唑，制备载药水凝胶及空白水凝胶，再冷冻干燥形成半渗透聚合网状物Semi-IPN。用扫描电镜观察性状结构，用测角仪测定其辛烷接触角，用电子天平测其在不同pH介质中的膨胀率，用红外测定了其特征峰，同时考察了载药水凝胶体外释药特性，初步药理实验判断其对实验性胃溃疡的疗效。结果 水凝胶具多孔性，且可很好地负载甲硝唑。辛烷接触角为(143.8±1.02)°，显示本品有较大的亲水性。膨胀率随pH的降低而增大，红外图谱说明水凝胶在酸性介质中膨胀时有-NH₂质子化。甲硝唑在酸性介质中的释放也随pH降低而增大，在pH 1.0介质中，3 h达最大释放量87%。初步药理实验表明，与对照组及甲硝唑片治疗组相比，该甲硝唑水凝胶对胃溃疡具有较优的治疗作用（P分别<0.01及P<0.05）。结论 甲硝唑水凝胶具有pH-敏感膨胀性，可改善甲硝唑对实验性胃溃疡的治疗作用，可作为治疗胃溃疡的新型胃部控释系统研究开发。     

Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway.

Cyclophosphamide (CY) and its derivative ifosfamide are alkylating agents used to treat osteosarcoma (OS). The purpose of these studies was to determine whether alkylating agents affect the expression of Fas ligand (FasL) and whether interleukin 12 enhances the sensitivity of human OS cells to alkylating agents. 4-Hydroperoxycyclophosphamide (4-HC), the preactivated CY compound, and 4-hydroperoxydidechlorocloclophosphamide (4-HDC), its nonalkylating analogue, human OS LM6 cells, and a clone of cells derived by transfection with the interleukin 12 gene (LM6-#6) were used for these studies. Incubation of LM6 and LM6-#6 with 10 micro M 4-HC increased the expression of FasL mRNA (2.5- and 3.0-fold, respectively). By contrast, 4-HDC, Adriamycin (ADR), cisplatin (CDP), and methotrexate (MTX) had no effect on FasL mRNA expression. Increased FasL expression after treatment with 4-HC was also demonstrated by immunohistochemistry and flow cytometry. Drug-induced FasL was functional and mediated cell death. We examined the effect of FasL up-regulation by 4-HC on LM6 and LM6-#6 cells. Flow cytometry showed that LM6-#6 cells expressed 2.2-fold more Fas than LM6 cells. Cytotoxicity of 4-HC, 4-HDC, ADR, CDP, and MTX on LM6, LM6-neo, and LM6-#6 were quantified. Colony-forming assay revealed an IC(50) of 2.10 micro M for 4-HC in LM6-neo cells compared with 0.41 micro M in LM6-#6 cells. The IC(50) for 4-HDC, ADR, CDP, and MTX were not significantly different between the two cell lines. We concluded that the increased expression of Fas enhanced LM6-#6 sensitivity to 4-HC. These data indicate that Fas/FasL may be involved in the cytotoxic pathway of CY. Combining biological agents with chemotherapeutic agents that have complementary Fas/FasL pathway actions may offer new therapeutic alternatives.     

Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.

PURPOSE: The process of metastasis requires the single tumor cell that seeds the metastatic clone to complete a complex series of steps. Identifying factors responsible for these steps is essential in developing and improving targeted therapy for metastasis. Resistance to receptor-mediated cell death, such as the Fas/Fas ligand pathway, is one mechanism commonly exploited by metastatic cell populations. EXPERIMENTAL DESIGN AND RESULTS: LM7, a subline of the SAOS human osteosarcoma cell line with low Fas expression, was selected for its high metastatic potential in an experimental nude mouse model. When transfected with the full-length Fas gene (LM7-Fas), these cells expressed higher levels of Fas than the parental LM7 cells or LM7-neo control-transfected cells. These cells were also more sensitive to Fas-induced cell death than controls. When injected intravenously into nude mice, the LM7-Fas cell line produced a significantly lower incidence of tumor nodules than control cell lines. Lung weight and tumor nodule size were also decreased in those mice injected with LM7-Fas. Levels of Fas were quantified in osteosarcoma lung nodules from 17 patients. Eight samples were Fas negative, whereas the remaining 9 were only weakly positive compared with normal human liver (positive control). CONCLUSIONS: Our results demonstrate that altering Fas expression can impact the metastatic potential of osteosarcoma cells. We conclude that the increase of Fas on the surface of the LM7 osteosarcoma cells increased their sensitivity to Fas-induced cell death in the microenvironment of the lung, where Fas ligand is constitutively expressed. Thus, loss of Fas expression is one mechanism by which osteosarcoma cells may evade host resistance mechanisms in the lung, increasing metastatic potential. Fas may therefore be a new therapeutic target for osteosarcoma.     

扁桃体周脓肿感染途径的探讨

为探讨扁桃体周脓肿的真正发病机理、感染途径，对连续诊治的１３１例扁周脓肿患者进行研究。其中８３例患侧的扁桃体被切除，切除之扁桃体外侧面均平整。通过８３例组织学观察，扁桃体上极表面既无扁桃溃破亦无脓瘘，邻接扁桃体上方之软腭粘膜下发现有感染及／或纤维化的小唾液腺（Ｗｅｂｅｒ腺），这些与扁桃体相邻的腺体在其他非扁周脓肿患者则显示正常形态与结构。从而认为扁桃体周围的化脓性感染可能与Ｗｅｂｅｒ腺有关，而非急性扁桃体炎。主张早期扁桃体切除术治疗扁周脓肿，目的在于获得充分引流。     

子宫内膜异位症的中医治疗进展

子宫内膜异位症（cndomctriosis，EM）是指具有生长功能的子宫内膜组织出现在子宫腔面以外的部位引起的病症。EM常表现为剧烈痛经或持续性下腹痛、月经失调、不孕、性交痛，以及受累器官部位出现错综复杂的相应症状，如血尿、便血等，对妇女身心健康造成极大的伤害。近年来其发病率越来越高，估计人群中约15％的妇女患本病，有报道其可占妇科经腹手术的10％～25％，本病虽属良性疾病，但具有远处转移和种植等恶性形为，并且是造成不孕或慢性盆腔疼痛的潜在原因，故子宫内膜异位症的治疗已成为当今妇科研究的重点之一。